{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:23:00Z","timestamp":1793658180884,"version":"4.5.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n IMPORTANCE<\/jats:title>\n Programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 inhibitors plus chemotherapy is the current standard first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). However, the long-term survival benefits at the 5-year benchmark remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n OBJECTIVE<\/jats:title>\n To determine whether adding camrelizumab to chemotherapy significantly improved 5-year overall survival (OS) as first-line treatment for RM-NPC, compared with chemotherapy alone.<\/jats:p>\n <\/jats:sec>\n \n DESIGN, SETTING, AND PARTICIPANTS<\/jats:title>\n The CAPTAIN-1st trial was a randomized, double-blind, phase 3 trial conducted at 28 hospitals in China. Between November 13, 2018, and November 29, 2019, patients with treatment-naive RM-NPC were enrolled. This secondary analysis of the CAPTAIN-1st trial was prespecified. Data analysis was conducted on June 1, 2025.<\/jats:p>\n <\/jats:sec>\n \n INTERVENTIONS<\/jats:title>\n Patients were randomized (1:1) to receive camrelizumab or placebo in combination with gemcitabine and cisplatin for 4 to 6 cycles, followed by maintenance therapy with camrelizumab or placebo until disease progression, unacceptable toxic effects, or completion of 2 years of treatment.<\/jats:p>\n <\/jats:sec>\n \n MAIN OUTCOME<\/jats:title>\n The primary end point, progression-free survival per independent review committee, has been reported previously. Herein, the secondary end point of OS is reported as prespecified in the protocol.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n \n Among 263 randomized patients (134 in randomized to camrelizumab, 129 to placebo), baseline characteristics were generally balanced between groups, except for age. The mean (SD) age was 49 (11.25) years, and 218 patients (82.9%) were male individuals, 45 (17.1%) were female individuals. With a median survival follow-up of 63.5 (95% CI, 61.2-64.6) months for the camrelizumab group and 63.0 (95% CI, 60.8-64.6) months for the placebo group, 85 (63.4%) and 95 (73.6%) deaths occurred, respectively. Median OS was 34.5 months (95% CI, 29.4-45.7) with camrelizumab vs 26.6 months (95% CI, 19.8-33.5) with placebo (hazard ratio [HR], 0.74; 95% CI, 0.55-0.99; 2-sided\n P<\/jats:italic>\n \u2009=\u2009.047). After adjusting for age imbalance, the HR was 0.65 (95% CI, 0.48-0.89;\n P<\/jats:italic>\n \u2009=\u2009.01). The 5-year OS rates were 37.8% vs 24.2%, reflecting an absolute difference of 13.6% (95% CI, 2.4%-24.8%;\n P<\/jats:italic>\n \u2009=\u2009.02) in favor of camrelizumab. The OS benefits were generally consistent across subgroups. In the camrelizumab group, patients who achieved rapid clearance of Epstein-Barr virus (EBV) DNA had significantly longer OS compared with those without EBV DNA clearance (HR, 0.32; 95% CI, 0.18-0.58;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS AND RELEVANCE<\/jats:title>\n In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1\u2013based chemoimmunotherapy in this setting.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03707509<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.6245","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:30:34Z","timestamp":1769704234000},"page":"295","source":"Crossref","is-referenced-by-count":13,"title":["Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma"],"prefix":"10.1001","volume":"12","author":[{"given":"Yan","family":"Huang","sequence":"first","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchen","family":"Sun","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Affiliated Tumor Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingao","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical School, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Xu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Gannan Medical University, Ganzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University Affiliated Oncology Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfang","family":"Shen","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Lang","sequence":"additional","affiliation":[{"name":"Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxiong","family":"Luo","sequence":"additional","affiliation":[{"name":"Liuzhou People\u2019s Hospital, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Fu","sequence":"additional","affiliation":[{"name":"900th Hospital of The Joint Logistics Team, PLA, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Qu","sequence":"additional","affiliation":[{"name":"Guangxi Zhuang Autonomous Region People\u2019s Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weineng","family":"Feng","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Foshan, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Lin","sequence":"additional","affiliation":[{"name":"Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xie","sequence":"additional","affiliation":[{"name":"General Hospital of Southern Theatre Command, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Li","sequence":"additional","affiliation":[{"name":"Yunnan Cancer Hospital, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[{"name":"Shantou University Medical College Affiliated Cancer Hospital, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lei","sequence":"additional","affiliation":[{"name":"Zhongshan People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianting","family":"Long","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Hong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Fujian Medical University\/Key Laboratory of Radiation Biology, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Jiujiang No.1 People\u2019s Hospital of Nanchang University, Jiujiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[{"name":"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanpei","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10192","key":"coi250086r1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma.","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"coi250086r2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"coi250086r3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"coi250086r4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"coi250086r5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi250086r6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"coi250086r7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309).","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"coi250086r8","doi-asserted-by":"publisher","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2025-CT011","article-title":"Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a global, multicenter, randomized, double-blind, phase 3 trial (AK105-304).","volume":"85","author":"Hu","year":"2025","journal-title":"Cancer Res"},{"issue":"16","key":"coi250086r9","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1200\/JCO.2025.43.16_suppl.6004","article-title":"Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R\/M NPC): results from a randomized, double-blind, phase 3 study.","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250086r10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN Guidelines Insights: head and neck cancers, version 2.2025.","volume":"23","author":"Colevas","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"coi250086r11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","article-title":"ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease.","volume":"34","author":"Bossi","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"coi250086r12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"20","key":"coi250086r13","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial.","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"coi250086r14","doi-asserted-by":"publisher","first-page":"S1554","DOI":"10.1016\/j.annonc.2024.10.426","article-title":"403O Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study.","volume":"35","author":"Fang","year":"2024","journal-title":"Ann Oncol"},{"issue":"16","key":"coi250086r15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"coi250086r16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study.","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250086r17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III Trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer.","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250086r18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"10125","key":"coi250086r19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37?513?025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"coi250086r20","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-20-3519","article-title":"Dynamic changes of post-radiotherapy plasma Epstein-Barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer.","volume":"27","author":"Hui","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"24","key":"coi250086r21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"21","key":"coi250086r22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"coi250086r23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02).","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250086r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy.","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"coi250086r25","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial.","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"coi250086r26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi250086r27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial.","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"16","key":"coi250086r28","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1200\/JCO.2025.43.16_suppl.6010","article-title":"Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: the EP-STAR trial.","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi250086r29","doi-asserted-by":"publisher","first-page":"TPS6123","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6123","article-title":"RIBBON-UM: treatment individualisation by EBV stratification in nasopharyngeal carcinoma (NPC): a phase 2, multi-arm umbrella platform trial.","volume":"43","author":"Chua","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2844192\/jamaoncology_huang_2026_oi_250086_1773666434.35122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:00:22Z","timestamp":1773932422000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2844192"}},"subtitle":["A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.6245","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}